Nuformix plc (FRA:1RT)

Germany flag Germany · Delayed Price · Currency is EUR
0.0010
-0.0005 (-33.33%)
At close: Nov 28, 2025
100.00%
Market Cap6.62M
Revenue (ttm)n/a
Net Income (ttm)-4.51M
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0010
Previous Close0.0015
Day's Range0.0010 - 0.0010
52-Week Range0.0005 - 0.0190
Betan/a
RSI46.10
Earnings DateDec 30, 2025

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP0... [Read more]

Industry Pharmaceutical Preparations
Founded 2008
Employees 3
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1RT
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

News

There is no news available yet.